Impact News +++ Why Iovance Biotherapeutics Stock Was Climbing Today (Fool) +++ IOVANCE Aktie -3,21%

AXSOME Aktie

>AXSOME Aktienkurs

95 EUR -0.2% (Tradegate)

Ask: 95.74 EUR / 450 Stück

Bid: 95.42 EUR / 450 Stück

Tagesumsatz: 51 Stück

Realtime Kurs von 8 bis 22 Uhr!

AXSOME Aktie über LYNX handeln

Intraday

1 Jahr

>AXSOME Performance

1 Woche: +6,7%

1 Monat: -0,9%

3 Monate: -1,5%

6 Monate: -23,4%

1 Jahr: +20,9%

laufendes Jahr: +26,1%

>AXSOME Aktie

Name:

AXSOME THERAPEUT. DL-0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US05464T1043 / A2AA7B

Symbol/ Ticker:

19X (Frankfurt) / AXSM (NASDAQ)

Kürzel:

FRA:19X, ETR:19X, 19X:GR, NASDAQ:AXSM

Index:

Webseite:

https://axsome.com/

Profil:

Axsome Therapeutics Inc. specializes in the develo..
>Volltext..

Marktkapitalisierung:

4749.63 Mio. EUR

Unternehmenswert:

4682.12 Mio. EUR

Umsatz:

423.98 Mio. EUR

EBITDA:

-171.09 Mio. EUR

Nettogewinn:

-211.46 Mio. EUR

Gewinn je Aktie:

-4.34 EUR

Schulden:

191.32 Mio. EUR

Liquide Mittel:

259.53 Mio. EUR

Operativer Cashflow:

-103.32 Mio. EUR

Bargeldquote:

0.89

Umsatzwachstum:

54.42%

Gewinnwachstum:

27.24%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

AXSOME

Letzte Datenerhebung:

19.08.25

>AXSOME Kennzahlen

Aktien/ Unternehmen:

Aktien: 49.9 Mio. St.

Frei handelbar: 82.14%

Leerverk. Aktien: 7.58%

Rückkaufquote: -2.35%

Mitarbeiter: 683

Umsatz/Mitarb.: 0.48 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 58.84%

Bewertung:

KGV: -

KGV lG: -

KUV: 11.08

KBV: 75.89

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 89.78%

Gewinnmarge: -49.88%

Operative Marge: -42.05%

Managementeffizenz:

Gesamtkaprendite: -41.57%

Eigenkaprendite: -280.68%

>AXSOME Peer Group

Es sind 601 Aktien bekannt.

>AXSOME Chart & Kurs - NASDAQ

>AXSOME News

05.08.25 - 19:00	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
	Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales....

04.08.25 - 20:54	Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 16:30	Here′s What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings (Zacks)
	While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

04.08.25 - 16:00	Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
	Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

04.08.25 - 15:18	Where Axsome Therapeutics Stands With Analysts (Benzinga)
	Latest Ratings for AXSM DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsOutperform Nov 2021SVB LeerinkMaintainsOutperform Aug 2021HC Wainwright & Co.MaintainsBuy View More Analyst Ratings for AXSM View the Latest Analyst Ratings read more...

04.08.25 - 14:36	Axsome (AXSM) Q2 Revenue Soars 72% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 13:06	Axsome Therapeutics GAAP EPS of -$0.97 beats by $0.15, revenue of $150.04M beats by $12.02M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 13:03	Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially...

28.07.25 - 17:30	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
	Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

21.07.25 - 13:33	Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline (GlobeNewswire EN)
	Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses...

21.07.25 - 13:03

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today (GlobeNewswire EN)

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today....

09.07.25 - 13:03

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 (GlobeNewswire EN)

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update....

07.07.25 - 13:03

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 (GlobeNewswire EN)

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-stage CNS pipeline....

24.06.25 - 05:01	Insiderhandel: General Counsel verkauft Aktien von Axsome Therapeutics im Wert von 768525 USD (Insiderkauf)
	Murdock, Hunter R. - Vorstand - Tag der Transaktion: 2025-06-20...

24.06.25 - 05:01	Insiderhandel: General Counsel verkauft Aktien von Axsome Therapeutics im Wert von 602122 USD (Insiderkauf)
	Murdock, Hunter R. - Vorstand - Tag der Transaktion: 2025-06-23...

20.06.25 - 13:03

Axsome Therapeutics Champions Brain Health During Alzheimer′s & Brain Awareness Month (GlobeNewswire EN)

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during this year's Alzheimer's & Brain Awareness Month....

19.06.25 - 07:01	Insiderhandel: General Counsel verkauft Aktien von Axsome Therapeutics im Wert von 768150 USD (Insiderkauf)
	Murdock, Hunter R. - Vorstand - Tag der Transaktion: 2025-06-16...

19.06.25 - 07:01	Insiderhandel: General Counsel verkauft Aktien von Axsome Therapeutics im Wert von 756750 USD (Insiderkauf)
	Murdock, Hunter R. - Vorstand - Tag der Transaktion: 2025-06-18...

19.06.25 - 07:01	Insiderhandel: General Counsel verkauft Aktien von Axsome Therapeutics im Wert von 751950 USD (Insiderkauf)
	Murdock, Hunter R. - Vorstand - Tag der Transaktion: 2025-06-17...

18.06.25 - 13:03

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) (GlobeNewswire EN)

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, in Minneapolis, Minnesota....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Täglich sterben wir: Täglich nämlich wird hinweggenommen ein Teil des Lebens, und auch dann, wenn wir wachsen, nimmt das Leben ab. - Seneca

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram